Applying interventions designed to reduce and manage the symptoms of substance use disorders.
Treatment
The social context of drinking among LGBT+ people
Professor Carol Emslie and David Barbour discuss research on gender, identity and drinking, and the disproportionate impact of substance use in the LGBT+ community.
Stress, Coping, and Context: Examining Substance Use Among LGBTQ Young Adults With Probable Substance Use Disorders
In this research, the authors explored how lesbian, gay, bisexual, transgender, and queer (LGBTQ) young adults with problematic substance use made sense of their substance use in relation to their LGBTQ identities. The authors interviewed...
LGBTQ+ People and Alcohol
This briefing provides a summary of alcohol consumption, alcohol harm, alcohol treatment, and gaps in knowledge regarding alcohol use among LGBTQ+ people. It uses the acronym LGBTQ+ to include lesbian, gay, bisexual, transgender, queer...
Substance Use in the LGBTQ+ Community: Reading List
Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ+) Pride month is celebrated each year during the month of June. Here you can find a list of resources and research on the topic of substance use among the LGBTQ+ community. 1) This report...
Highlights from the 2023 UNODC World Drug Report
ISSUP are pleased to present our Webinar on highlights from the 2023 edition of the UNODC World Drug Report.
Highlights from the 2023 UNODC World Drug Report
Join our upcoming Webinar presenting highlights from the 2023 edition of the UNODC World Drug Report.
Treatment of Co-Occurring Traumatic Stress and Substance Use Problems Among Adolescents: State of the Science and Future Directions
In this presentation, Dr Carla Danielson will:
Treatment for drug and alcohol misuse should involve families and communities
Alcohol and other drug treatment are generally only provided for individuals, often away from their families. Treatment aims to improve well-being and reduce the harms of substance use and families and communities can play a significant...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
National DSD Integrated Programme and Web App ASSIST Launch
This launch event is in response to the call for integrated implementation of services in institutions of higher learning and colleges, especially, at the primary level of intervention by respective stakeholders to facilitate integrated early intervention and prevention programmes with a specific focus on social crime prevention, risky substance use, and gender-based violence.